Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Geneoscopy Appoints Amit Bhalla as Chief Financial Officer to Advance Strategic Growth and Support Commercialization Efforts

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the appointment of Amit Bhalla as Chief Financial Officer (CFO). Bhalla brings more than 25 years of experience in healthcare finance, strategy, and investment to support Geneoscopy’s continued expansion, including the commercial launch of ColoSense®, the company’s RNA-based, non-invasive colorectal cancer screening test.

“Amit’s extensive financial leadership and deep understanding of the healthcare landscape will be invaluable as we scale our operations and advance our mission of improving patient outcomes through innovative diagnostic solutions,” said Andrew Barnell, Chief Executive Officer of Geneoscopy. “Following our recent $105 million Series C financing, Amit’s expertise will be instrumental in optimizing our financial strategy as we continue our work to bring ColoSense to market and progress our pipeline of products for inflammatory bowel disease (IBD).”

Bhalla most recently served as Executive Vice President and CFO at Sampled, a global biorepository and laboratory, where he led the financial, supply chain, and facilities operations. Before that, Bhalla served as Vice President of Global Strategy & Development and was a member of the Executive Management Committee at Becton Dickinson. His career also includes almost two decades on Wall Street as a lead healthcare analyst for Lord Abbett’s Value Funds, Director of Equity Research at Citi, and Vice President at Morgan Stanley, where he covered the life science tools, diagnostics, and medical device industries.

“This is an exciting time to join Geneoscopy’s leadership team, and I look forward to leveraging my background and experience to support its growth trajectory,” said Bhalla. “With a strong financial foundation, a differentiated solution for colorectal cancer screening, and the resources to drive meaningful innovation, the company is well-positioned to transform gastrointestinal diagnostics, bringing life-changing solutions to more patients.”

Geneoscopy recently secured $105 million in Series C financing to support the commercial launch of ColoSense, which received FDA approval in May 2024 as a noninvasive colorectal cancer screening test for eligible adults. The funding will also accelerate Geneoscopy’s precision medicine approach for IBD and further advance its proprietary RNA technology platform.

About Geneoscopy, Inc.

Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.